Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion

Ju-Qiong Wang, Liang-Liang Li, Ao Hu, Gang Deng, Jian Wei, Yun-Feng Li, Yuan-Bin Liu, Xiao-Yi Lu, Zhi-Ping Qiu, Xiong-Jie Shi, Xiaolu Zhao, Jie Luo and Bao-Liang Song ()
Additional contact information
Ju-Qiong Wang: Wuhan University
Liang-Liang Li: Wuhan University
Ao Hu: Wuhan University
Gang Deng: Wuhan University
Jian Wei: Wuhan University
Yun-Feng Li: Wuhan University
Yuan-Bin Liu: Wuhan University
Xiao-Yi Lu: Wuhan University
Zhi-Ping Qiu: Wuhan University
Xiong-Jie Shi: Wuhan University
Xiaolu Zhao: Wuhan University
Jie Luo: Wuhan University
Bao-Liang Song: Wuhan University

Nature, 2022, vol. 608, issue 7922, 413-420

Abstract: Abstract High cholesterol is a major risk factor for cardiovascular disease1. Currently, no drug lowers cholesterol through directly promoting cholesterol excretion. Human genetic studies have identified that the loss-of-function Asialoglycoprotein receptor 1 (ASGR1) variants associate with low cholesterol and a reduced risk of cardiovascular disease2. ASGR1 is exclusively expressed in liver and mediates internalization and lysosomal degradation of blood asialoglycoproteins3. The mechanism by which ASGR1 affects cholesterol metabolism is unknown. Here, we find that Asgr1 deficiency decreases lipid levels in serum and liver by stabilizing LXRα. LXRα upregulates ABCA1 and ABCG5/G8, which promotes cholesterol transport to high-density lipoprotein and excretion to bile and faeces4, respectively. ASGR1 deficiency blocks endocytosis and lysosomal degradation of glycoproteins, reduces amino-acid levels in lysosomes, and thereby inhibits mTORC1 and activates AMPK. On one hand, AMPK increases LXRα by decreasing its ubiquitin ligases BRCA1/BARD1. On the other hand, AMPK suppresses SREBP1 that controls lipogenesis. Anti-ASGR1 neutralizing antibody lowers lipid levels by increasing cholesterol excretion, and shows synergistic beneficial effects with atorvastatin or ezetimibe, two widely used hypocholesterolaemic drugs. In summary, this study demonstrates that targeting ASGR1 upregulates LXRα, ABCA1 and ABCG5/G8, inhibits SREBP1 and lipogenesis, and therefore promotes cholesterol excretion and decreases lipid levels.

Date: 2022
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41586-022-05006-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:608:y:2022:i:7922:d:10.1038_s41586-022-05006-3

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-022-05006-3

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().